Articles from Bora Biologics
Partnership includes development and manufacturing support for multiple monoclonal and bispecific antibody programs targeting U.S. and global animal health markets
By Bora Biologics · Via ACCESS Newswire · October 4, 2026
Successful scale-up to commercial production supports long-term supply agreement for Q Sera's patented RAPClot technology
By Bora Biologics · Via ACCESS Newswire · September 14, 2026
Expansion Scales U.S. Single-Use Drug Substance Capacity to 20,000 Liters Across Two FDA-Registered Facilities
By Bora Biologics · Via ACCESS Newswire · July 13, 2026